Key Insights

Highlights

Treatment Research

6 treatments under study, led by No Topical Infliximab

Research Leaders

10 sponsors active, led by Ocular Therapeutix, Inc.

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 90/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

3Total

Not Applicable (1)

Phase 1/2 (1)

Phase 4 (1)

Trial Status

Recruiting2

Unknown1

Terminated1

Clinical Trials (4)

Showing 4 of 4 trials

NCT07780916Recruiting

Long-Term Clinical Results of Ab-Interno Trabeculotomy in Glaucoma Management

NCT05180994Phase 1/2RecruitingPrimary

Topical Infliximab in Eyes With Penetrating Keratoplasty

NCT05790408Not ApplicableTerminated

Anterior-segment OCT (AS-OCT) and Intraoperative OCT (iOCT) for Trans- Conjunctival Needle Revision (TCNR)

NCT05116345Phase 4UnknownPrimary

DEXTENZA for the Treatment of Pain and Inflammation Following Surgical Trabeculectomy and Ahmed Valve Procedures

Showing all 4 trials

Research Network

Common Treatments

No Topical Infliximab1
Abinterno Trabeculotomy1
Digital Microscope Integrated With Intraoperative Oct Zeiss Artevo 800 Carl Zeiss Meditec Ag1
Dexamethasone1
Infliximab1

Active Sponsors

Ocular Therapeutix, Inc.1
Centre hospitalier de l'Université de Montréal (CHUM)1
Prism Eye Institute1
Ottawa Hospital Research Institute1
Niagara Health System1

Glaucoma Following Surgery